FINWIRES · TerminalLIVE
FINWIRES

HKG:1228

3 stories mentioning HKG:1228Updated 2d ago

Every FINWIRES story that references HKG:1228, newest first.

Asia

Hong Kong Stocks Edge Higher on Friday; Xiaomi Plummets 7%

Hong Kong stocks ended slightly higher on Friday, tracking broader Asian gains as investors weighed strength in global technology shares against ongoing uncertainty over interest rates.The Hang Seng Index rose 25.55 points, or 0.1%, to close at 25,884.43, while the Hang Seng China Enterprises Index fell 32.56 points, or 0.4%, to 8,612.15.Strong earnings from major U.S. technology companies lifted chipmakers and helped ease concerns over artificial intelligence-related spending. Meanwhile, oil prices declined as supply flows through key shipping routes improved despite limited progress in U.S.-Iran talks.Among individual stocks, Xiaomi (HKG:1810) dropped nearly 7% after unveiling its SkyNomad extended-range SUV series as it expands further into China's electric vehicle market.CANbridge Pharmaceuticals (HKG:1228) gained 1% after starting registration procedures and commercial preparations to launch its Gaucher disease therapy, Gaurunning, in a North African market.

Hang SengHKG:1228HKG:1810
Asia

CANbridge Pharma Starts Registration for Gaucher Drug in North Africa; Shares Up 6%

CANbridge Pharmaceuticals (HKG:1228) has begun registration procedures and commercial preparations to launch its Gaucher disease therapy, Gaurunning, in a key North African market, according to a Thursday Hong Kong bourse filing.The company said the move represents the first step in Gaurunning's international rollout and targets a market with significant unmet clinical needs.Gaurunning, an enzyme replacement therapy for Type I and Type III Gaucher disease, received approval from China's National Medical Products Administration in May 2025 for adolescents aged 12 and above and adults.Shares of the pharmaceutical firm rose nearly 6% in recent trading.

HKG:1228
Asia

CANbridge Pharmaceuticals Enters Service Agreements With WuXi Biologics, Baheal Medical

CANbridge Pharmaceuticals (HKG:1228) entered service procurement framework agreements with WuXi Biologics and Baheal Medical, according to a Tuesday Hong Kong bourse filing.Under the agreement, WuXi Biologics (HKG:2269) will provide contract research, development, and manufacturing organization services to CANbridge through 2028.Meanwhile, Baheal Medical will provide logistics, warehousing, and other supporting services through 2028.

HKG:1228HKG:2269

Track with the FINWIRES app suite